Substantiation of Using Pimecrolimus 1% Cream in Proactive Therapy of Children with Atopic Dermatitis
Nikolay N. Murashkin,
Roman A. Ivanov,
Eduard T. Ambarchian,
Roman V. Epishev,
Alexander I. Materikin,
Leonid A. Opryatin,
Alena A. Savelova https://doi.org/10.15690/vsp.v20i5.2310
Abstract
Atopic dermatitis (AtD) is multifactorial inflammatory skin disease with high prevalence in pediatric population. It is crucial to implement long-term maintenance therapy to prevent AtD exacerbations according to current clinical guidelines and expert reports. The article summarizes the results of the major studies on using pimecrolimus 1% cream. Its efficacy and safety in long-term proactive therapy of children with AtD are presented.
Keywords
atopic dermatitis,
pimecrolimus,
proactive therapy,
maintenance therapy,
lymphoma,
atrophy,
topical calcineurin inhibitor,
children
Supporting agencies: The article has been funded by Viatris.
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children's Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Nikolay N. Murashkin — receiving research grants from pharmaceutical companies Janssen, Eli Lilly, Novartis. Scientific consultant of Galderma, Pierre Fabre, Bayer, LEO Pharma, Pfizer, AbbVie, Amryt Pharma, Zeldis Pharma.
Roman A. Ivanov
National Medical Research Center of Children's Health; Central State Medical Academy
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
No conflict of interests.
Eduard T. Ambarchian
Research Institute of Pediatrics and Children's Health in “Central Clinical Hospital of the Russian Academy of Sciences”
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Eduard T. Ambarchyan — receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Janssen, Amryt Pharma.
Roman V. Epishev
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Roman V. Epishev — receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Amryt Pharma.
Alexander I. Materikin
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Alexander I. Materikin — receiving research grants from pharmaceutical companies Eli Lilly, Novartis, AbbVie, Amryt Pharma.
Leonid A. Opryatin
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
No conflict of interests.
Alena A. Savelova
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
No conflict of interests.
References
1. Maliyar K, Sibbald C, Pope E, et al. Diagnosis and Management of Atopic Dermatitis. Adv Skin Wound Care. 2018;31(12):538-550. doi: 10.1097/01.asw.0000547414.38888.8d
2. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743. doi: 10.1016/s0140-6736(06)69283-0
3. Busse WW. The atopic march: Fact or folklore? Ann Allergy Asthma Immunol. 2018;120(2):116-118. doi: 10.1016/j.anai.2017.10.029
4. Kemp AS. Cost of Illness of Atopic Dermatitis in Children. Pharmacoeconomics. 2003;21(2):105-113. doi: 10.2165/00019053-200321020-00003
5. Kowalska-Olędzka E, Czarnecka M, Baran A, et al. Epidemiology of atopic dermatitis in Europe. J Drug Assess. 2019;8(1):126–128. doi: 10.1080/21556660.2019.1619570
6. Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121(4):947-954. e15. doi: 10.1016/j.jaci.2007.11.004
7. Mallol J, Crane J, von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (Madr). 2013;41(2):73-85. doi: 10.1016/j.aller.2012.03.001
8. David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol. 2017;1027:21-37. doi: 10.1007/978-3-319-64804-0_3
9. Cork MJ, Danby SG, Vasilopoulos Y, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-1908. doi: 10.1038/jid.2009.133
10. Sroka-Tomaszewska J, Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int J Mol Sci. 2021;22(8):4130. doi: 10.3390/ijms22084130
11. Brown SJ, Asai Y, Cordell HJ, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol. 2011;127(3):661-667. doi: 10.1016/j.jaci.2011.01.031
12. Marenholz I, Kerscher T, Bauerfeind A, et al. An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. J Allergy Clin Immunol. 2009;123(4):911-916. doi: 10.1016/j.jaci.2009.01.051
13. Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol. 2006;118(1):214-219. doi: 10.1016/j.jaci.2006.05.004
14. Matsunaga MC, Yamauchi PS. IL-4 and IL-13 Inhibition in Atopic Dermatitis. J Drugs Dermatol. 2016;15(8):925-929.
15. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150-155. doi: 10.1016/j.jaci.2007.04.031
16. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84-92. doi: 10.2500/aap.2019.40.4202
17. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411-417. doi: 10.1016/j.jaci.2005.10.033
18. Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol. 2018;141(1):1677-1689.e8. doi: 10.1016/j.jaci.2017.12.1002
19. Turner MJ, Zhou B. A new itch to scratch for TSLP. Trends Immunol. 2014;35(2):49-50. doi: 10.1016/j.it.2013.12.001
20. Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(2):239-250. doi: 10.1111/jdv.15973
21. Fujii M. Current Understanding of Pathophysiological Mechanisms of Atopic Dermatitis: Interactions among Skin Barrier Dysfunction, Immune Abnormalities and Pruritus. Biol Pharm Bull. 2020;43(1):12-19. doi: 10.1248/bpb.b19-00088
22. Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8-13. doi: 10.1016/j.alit.2016.10.005
23. Rinaldi G. The Itch-Scratch Cycle: A Review of the Mechanisms. Dermatol Pract Concept. 2019;9(2):90-97. doi: 10.5826/dpc.0902a03
24. Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2013;69(1):17-27. doi: 10.1111/all.12268
25. Kapoor R, Menon C, Hoffstad O, et al. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68-73. doi: 10.1016/j.jaad.2007.06.041
26. Lack G. Update on risk factors for food allergy. J Allergy Clin Immunol. 2012;129(5):1187-1197. doi: 10.1016/j.jaci.2012.02.036
27. Kelleher MM, Dunn-Galvin A, Gray C, et al. Skin barrier impairment at birth predicts food allergy at 2 years of age. J Allergy Clin Immunol. 2016;137(4):1111-1116.e8. doi: 10.1016/j.jaci.2015.12.1312
28. Mullins RJ, Wainstein BK, Barnes EH, et al. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy. 2016;46(8):1099-1110. doi: 10.1111/cea.12748
29. Wollenberg A, Christen-Zach S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-2744. doi: 10.1111/jdv.16892
30. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: 10.1111/jdv.14888
31. Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol. 2012;24(3):253-260. doi: 10.5021/ad.2012.24.3.253
32. Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges. 2009;7(2):117-121. doi: 10.1111/j.1610-0387.2008.06772.x
33. Macheleidt O, Kaiser HW, Sandhoff K. Deficiency of epidermal proteinbound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol. 2002;119(1):166-173. doi: 10.1046/j.1523-1747.2002.01833.x
34. Wollenberg A, Rawer HC, Schauber J. Innate immunity in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):272-281. doi: 10.1007/s12016-010-8227-x
35. Arakawa H, Shimojo N, Katoh N, et al. Consensus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan: Goals of treatment and topical therapy. Allergol Int. 2020;69(1):84-90. doi: 10.1016/j.alit.2019.08.006
36. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis — an emerging concept. Allergy. 2009;64(2):276-278. doi: 10.1111/j.1398-9995.2008.01803.x
37. Peserico A, Stadtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158(4):801-807. doi: 10.1111/j.1365-2133.2008.08436.x
38. Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(7):742-750.
39. Carr WW. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations. Paediatr Drugs. 2013;15(4):303-310. doi: 10.1007/s40272-013-0013-9
40. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045-1060. doi: 10.1111/j.1468-3083.2012.04635.x
41. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Exp Ophthalmol. 2004;32(2):224-226. doi: 10.1111/j.1442-9071.2004.00787.x
42. Gschwind H-P, Waldmeier F, Zollinger M, et al. Pimecrolimus: Skin disposition after topical administration in minipigs in vivo and in human skin in vitro. Eur J Pharm Sci. 2008;33(1):9-19. doi: 10.1016/j.ejps.2007.09.004
43. Weiss HM, Fresneau M, Moenius T, et al. Binding of pimecroli-mus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos. 2008;36(9):1812-1818. doi: 10.1124/dmd.108.021915
44. Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-814. doi: 10.1111/j.1365-2133.2011.10449.x
45. Gutfreund K, Bienias W, Szewczyk A, KaszubaA. Topical calcineu-rin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30(3):165-169. doi: 10.5114/pdia.2013.35619
46. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol. 2004;122(3):673-684. doi: 10.1111/j.0022-202X.2004.22324.x
47. Sambyal K, Singh RV. Bioprocess and genetic engineering aspects of ascomycin production: a review. J Genet Eng Biotechnol. 2020;18(1):73. doi: 10.1186/s43141-020-00092-0
48. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, doubleblind controlled study. Br J Dermatol. 2001;144(3):507-513. doi: 10.1046/j.1365-2133.2001.04076.x
49. Murrell DF, Calvieri S, Ortonne JP, et al. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. Br J Dermatol. 2007;157(5):954-959. doi: 10.1111/j.1365-2133.2007.08192.x
50. Grzanka A, Zebracka-Gala J, Rachowska R, et al. The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp Dermatol. 2012;21:184-188. doi: 10.1111/j.1600-0625.2011.01417.x
51. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;123(5):1124-1133. doi: 10.1016/j.jaci.2009.03.032
52. Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758-766. doi: 10.1684/ejd.2013.2169
53. Stander S, Schurmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag. 2006;2(2):213-218. doi: 10.2147/tcrm.2006.2.2.213
54. Stander S, Stander H, Seeliger S, et al. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol. 2007;156(5):1020-1026. doi: 10.1111/j.1365-2133.2007.07813.x
55. Luger T, Paller AS, Irvine AD, et al. Topical therapy of atopic dermatitis with a focus on pimecrolimus. J Eur Acad Dermatol Venereol. 2021;35(7):1505-1518. doi: 10.1111/jdv.17272
56. Sher LG, Chang J, Patel IB, et al. Relieving the pruritus of atopic dermatitis: a meta-analysis. Acta Derm Venereol. 2012;92(5):455-461. doi: 10.2340/00015555-1360
57. Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy. 2006;61(3):375-381. doi: 10.1111/j.1398-9995.2005.00977.x
58. Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi: 10.1542/peds.2014-1990
59. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecro-limus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: 10.1542/peds.110.1.e2
60. Murashkin NN, Makarova SG, Grigorev SG, et al. Prevention of Transcutaneous Sensitization to Cow Milk Proteins in Infants with Atopic Dermatitis: Cohort Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2020;19(6):538-544. (In Russ). doi: 10.15690/vsp.v19i6.2152
61. Fedorov DV, Murashkin NN, Makarova SG., Ivanov RA. Strategies for Selecting Therapeutic Tactics for Reducing Transcutaneous Sensibilisation Risk in Infants with Atopic Dermatitis: Cohort Retrospective Prospective Study. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2021;18(1):8-16. (In Russ). doi: 10.15690/pf.v18i1.2219
62. Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006;117(1):e118-e128. doi: 10.1542/peds.2005-1188
63. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52(2):247-253. doi: 10.1016/j.jaad.2004.08.046
64. Papp KA, Werfel T, Folster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol. 2005;52(2):240-246. doi: 10.1016/j.jaad.2004.09.016
65. Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121-131. doi: 10.2165/00128071-200607020-00005
66. Legendre L, Barnetche T, Mazereeuw-Hautier J, et al. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992-1002. doi: 10.1016/j.jaad.2015.02.1116
67. Paller AS, Folster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375-381. doi: 10.1016/j.jaad.2020.03.075
68. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51(4):515-525. doi: 10.1016/j.jaad.2004.01.051
69. Reda AM, Elgendi A, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatol Treat. 2019;30(4):366-373. doi: 10.1080/09546634.2018.1524823
70. Murashkin NN, Epishev RV, Fedorov DV, et al. Sensitive Skin Syndrome in Children with Atopic Dermatitis: Pathogenesis and Management Features. Voprosy sovremennoi pediatrii — Current Pediatrics. 2019;18(4):285-293. (In Russ). doi: 10.15690/vsp.v18i4.2046
Review
For citations:
Murashkin N.N., Ivanov R.A., Ambarchian E.T., Epishev R.V., Materikin A.I., Opryatin L.A., Savelova A.A. Substantiation of Using Pimecrolimus 1% Cream in Proactive Therapy of Children with Atopic Dermatitis. Current Pediatrics. 2021;20(5):376-382. (In Russ.) https://doi.org/10.15690/vsp.v20i5.2310
Views:
877
Email this article 
